Completed PHASE3 INTERVENTIONAL NCT00320398

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in Prevention of Venous Thromboembolism After Elective Total Hip Replacement Surgery

Sponsor: GlaxoSmithKline

Conditions Thrombosis, Venous

Interventions Fondaparinux

Updated 9 times since 2017 Last updated: Aug 30, 2018 Started: Jan 30, 2006 Primary completion: Jul 18, 2006 Completion: Jul 18, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Thrombosis, Venous, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 9 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2018 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Oct 2018 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2018 — Jun 2018 [monthly]

Completed PHASE3
Jul 2017 — Jan 2018 [monthly]

Completed PHASE3
May 2017 — Jul 2017 [monthly]

Completed PHASE3
Jan 2017 — May 2017 [monthly]

Completed PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.